PLACENTEX CREMA 25G 0.08%

PLACENTEX 0.08% CREMA

active ingredients

A 25 g tube contains: Active Principle: Polydesossiribonucleotide 80 mg Excipients with known effect: lanolin, cetilstearilic alcohol, alchil para-hydroxybenzoati, aromatic base For the full list of excipients, see paragraph 6.1

Excellent

Exterior of oleic acid of decilic alcohol, cetilstearilic alcohol, anidra lanolin, alchil parahydroxybenzoati, imidazolidinilurea, aromatic base (contains citral, eugenol, geranium, lemon, linalol, citronellol), purified water.

Therapeutic indications

Treatment with healing and antidistrophic action of small superficial wounds and ulcerations with limited interest to the epidermis.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.

Population

Local applications 1 or 2 times a day or second medical evaluation.

Conservation

This medicine does not require any special precaution for conservation. Store Placentex away from heat sources and protected from light.

Warnings

It is possible the occurrence of hypersensitivity phenomena to the components, which require the suspension of administration. Desensitizing medical therapy may be necessary. Important information about some excipients PLACENTEX 0.08% cream contains lanolin and cetilstearilic alcohol. They can cause local skin reactions (e.g. contact dermatitis). PLACENTEX 0.08% cream contains alchil para-hydroxybenzoates. They can cause allergic reactions (also delayed). PLACENTEX 0.08% cream contains an aromatic base, in turn containing citral, eugenol, geranium, lemon, linalol, citronellol. Citral, eugenol, geranium, lemon, linalol, citronellol may cause allergic reactions.

Interactions

Interaction studies have not been carried out.

Effects

Hypersensitivity reactions have been reported (see paragraph 4.4). Reporting of suspicious adverse reactions. The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazionireazioni-avverse.

Overdosing

No overdose cases have been reported.

Data concerning the use of Placentex in pregnant women do not exist or are in limited number.

Source: Farmadati